表紙
市場調查報告書

全球格林-巴利症候群市場(免疫球蛋白靜脈注射,血漿替換法,其他(止痛藥,抗痙攣劑,LMWH) - 全球產業分析,規模,佔有率,成長,趨勢,預測(2017∼2025年)

Guillain-Barre Syndrome Market (Intravenous Immunoglobulin, Plasma Exchange, Others (Analgesics, Anticonvulsants, LMWH)) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

出版商 Transparency Market Research 商品編碼 641002
出版日期 內容資訊 英文 194 Pages
商品交期: 最快1-2個工作天內
價格
全球格林-巴利症候群市場(免疫球蛋白靜脈注射,血漿替換法,其他(止痛藥,抗痙攣劑,LMWH) - 全球產業分析,規模,佔有率,成長,趨勢,預測(2017∼2025年) Guillain-Barre Syndrome Market (Intravenous Immunoglobulin, Plasma Exchange, Others (Analgesics, Anticonvulsants, LMWH)) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025
出版日期: 2018年04月25日內容資訊: 英文 194 Pages
簡介

本報告提供全球格林-巴利症候群市場相關調查,市場現狀與成長預測,各治療、各給藥途徑、各流通管道、各地區趨勢,及加入此市場的主要企業的簡介等彙整資料。

第1章 序論

第2章 假設和調查方法

第3章 摘要整理

第4章 市場概要

  • 概要
  • 市場規模預測
  • 市場預測
  • 主要市場發展
  • 波特五力分析
  • 3大公司的成功因素
  • 疾病概要
  • 主要的合併、收購
  • 開發平台分析
  • 主要的研究機關

第5章 市場趨勢

  • 促進要素
  • 阻礙要素
  • 機會分析
  • 機會

第6章 各治療市場分析

  • 簡介
  • 市場價值佔有率分析
  • 市場分析
  • 市場魅力度分析

第7章 各給藥途徑市場分析

  • 簡介
  • 市場價值佔有率分析
  • 市場分析
  • 市場魅力度分析

第8章 各流通管道市場分析

  • 簡介
  • 市場價值佔有率分析
  • 市場分析
  • 市場魅力度分析

第9章 各地區市場分析

  • 市場概要
  • 市場價值佔有率分析
  • 市場預測
  • 市場分析
  • 市場魅力度分析

第10章 北美市場

第11章 歐洲市場

第12章 亞太地區市場

第13章 其他各國

第14章 企業簡介

  • 市場佔有率分析
  • 競爭矩陣
  • 企業簡介
    • Grifols S.A.
    • CSL Behring LLC
    • Shire plc
    • Octapharma AG
    • 日本製藥株式會社
    • Akari Therapeutics, PLC
    • China Biologic Products Holdings, Inc.
    • Biotest AG
    • Kedrion s.p.A.
目錄

Guillain-Barre Syndrome Market - Overview:

This report on the global Guillain-Barre syndrome market studies the current as well as future prospects of the market globally. Stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of products for the treatment of Guillain-Barre syndrome as well as new entrants planning to enter the market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments considered in the scope of the study. It also provides the overall information and data analysis of the global Guillain-Barre syndrome market with respect to the leading market segments based on therapeutics, route of administration, distribution channel, and geography.

Based on therapeutics, the Guillain-Barre syndrome market has been segmented into intravenous immunoglobulin, plasma exchange, and others (analgesics, anticonvulsants, LMWH, etc.). In terms of route of administration, the market has been classified into oral and parenteral. In terms of distribution channel, the Guillain-Barre syndrome market has been divided into hospital pharmacies, retail pharmacies, and others (home care, clinics, etc.). Each of these segments have been extensively analyzed based on market-related factors such as rates of incidence and prevalence of Guillain-Barre syndrome and available treatment options for Guillain-Barre syndrome. Moreover, historical year-on-year growth has been taken into consideration while estimating the market size. The market size and forecast (in terms of US$ Mn) for each segment have been provided for the period from 2015 to 2025. The report also provides the compounded annual growth rate (CAGR %) for each segment for the period from 2017 to 2025, considering 2016 as the base year.

The market overview section of the report explores the market dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the Guillain-Barre syndrome market and that could also influence the market in the near future. Market attractiveness analysis has been provided in the market overview section in order to explain the degree of competition in the market across different geographies. The scenario of competition among different market players has been evaluated through market share analysis in the competition landscape section of the report. All these factors may help market players to take strategic decisions in order to strengthen their position and increase their share in the global Guillain-Barre syndrome market.

Geographically, the global Guillain-Barre syndrome market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these regions has been provided for the period from 2015 to 2025, along with the respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. The report also provides the market size and forecast for major countries in the respective region. A detailed qualitative analysis of factors responsible for driving and restraining the market and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis, Porter's five forces analysis, and market share analysis by key player, thereby presenting a thorough analysis of the overall competition scenario in the global Guillain-Barre syndrome market.

Key players operating in the global Guillain-Barre syndrome market are Grifols S.A., CSL Behring LLC, Shire plc, Octapharma AG, Nihon Pharmaceutical Co., Ltd., Akari Therapeutics, PLC, China Biologic Products Holdings, Inc., Biotest AG, and Kedrion s.p.A.

The global Guillain-Barre syndrome market has been segmented as follows:

Global Guillain-Barre Syndrome Market, by Therapeutics

  • Intravenous Immunoglobulin
  • Plasma Exchange
  • Others (Analgesics, Anticonvulsants, LMWH, etc.)

Global Guillain-Barre Syndrome Market, by Route of Administration

  • Oral
  • Parenteral

Global Guillain-Barre Syndrome Market, by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others (Home Care, Clinics, etc.)

Global Guillain-Barre Syndrome Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • U.K.
    • Rest of Europe
  • Asia Pacific
    • ASEAN
    • India
    • Japan
    • China
    • Rest of Asia Pacific
  • Rest of World

Table of Contents

1. Preface

  • 1.1. Report Scope and Market Segmentation
  • 1.2. Research Highlights

2. Assumptions and Research Methodology

  • 2.1. Assumptions
  • 2.2. Research Methodology

3. Executive Summary

  • 3.1. Global Guillain-Barre Syndrome Market Size (US$ Mn) and Distribution, by Geography, 2017 and 2025
  • 3.2. Global Guillain-Barre Syndrome Market Snapshot, 2016
  • 3.3. Global Guillain-Barre Syndrome Market: Opportunity Map

4. Market Overview

  • 4.1. Overview
  • 4.2. Global Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, 2015-2025
  • 4.3. Global Guillain-Barre Syndrome Market Outlook
  • 4.4. Global Guillain-Barre Syndrome Market: Key Market Developments
  • 4.5. Global Guillain-Barre Syndrome Market: Porter's Five Forces
  • 4.6. Global Guillain-Barre Syndrome Market: Key Success Factors of Top 3 Players
  • 4.7. Guillain-Barre Syndrome: Disease Overview
    • 4.7.1. Therapeutics
    • 4.7.2. Epidemiology
    • 4.7.3. Symptoms
    • 4.7.4. Etiology
    • 4.7.5. Pathophysiology
    • 4.7.6. Diagnosis
  • 4.8. Global Guillain-Barre Syndrome Market: Key Mergers & Acquisitions
  • 4.9. Guillain-Barre Syndrome: Pipeline Analysis
  • 4.10. Guillain-Barre Syndrome: Major Research Institutes Involved

5. Market Dynamics

  • 5.1. Drivers
  • 5.2. Restraints
  • 5.3. Opportunity Analysis
  • 5.4. Opportunities

6. Guillain-Barre Syndrome Market Analysis, by Therapeutics

  • 6.1. Introduction
  • 6.2. Global Guillain-Barre Syndrome Market Value Share Analysis, by Therapeutics
  • 6.3. Guillain-Barre Syndrome Market Analysis, by Therapeutics
    • 6.3.1. Intravenous Immunoglobulin
    • 6.3.2. Plasma Exchange
    • 6.3.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
  • 6.4. Guillain-Barre Syndrome Market Attractiveness Analysis, by Therapeutics

7. Guillain-Barre Syndrome Market Analysis, by Route of Administration

  • 7.1. Introduction
  • 7.2. Global Guillain-Barre Syndrome Market Value Share Analysis, by Route of Administration
  • 7.3. Guillain-Barre Syndrome Market Analysis, by Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
  • 7.4. Guillain-Barre Syndrome Market Attractiveness Analysis, by Route of Administration

8. Guillain-Barre Syndrome Market Analysis, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Global Guillain-Barre Syndrome Market Value Share Analysis, by Distribution Channel
  • 8.3. Guillain-Barre Syndrome Market Analysis, by Distribution Channel
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Others (Home Care, Clinics, etc.)
  • 8.4. Guillain-Barre Syndrome Market Attractiveness Analysis, by Distribution Channel

9. Guillain-Barre Syndrome Market Analysis, by Region

  • 9.1. Global Guillain-Barre Syndrome Market Snapshot, by Country
  • 9.2. Global Guillain-Barre Syndrome Market Value Share Analysis, by Region
  • 9.3. Global Guillain-Barre Syndrome Market Forecast, by Region
    • 9.3.1. North America
    • 9.3.2. Europe
    • 9.3.3. Asia Pacific
    • 9.3.4. Rest of World
  • 9.4. Global Guillain-Barre Syndrome Market Attractiveness Analysis, by Region
  • 9.5. Key Market Trends, by Region

10. North America Guillain-Barre Syndrome Market Analysis

  • 10.1. Key Findings
  • 10.2. North America Guillain-Barre Syndrome Market Overview
  • 10.3. North America Guillain-Barre Syndrome Market Value Share Analysis, by Therapeutics
  • 10.4. North America Guillain-Barre Syndrome Market Forecast, by Therapeutics
    • 10.4.1. Intravenous Immunoglobulin
    • 10.4.2. Plasma Exchange
    • 10.4.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
  • 10.5. North America Guillain-Barre Syndrome Market Value Share Analysis, by Route of Administration
  • 10.6. North America Guillain-Barre Syndrome Market Forecast, by Route of Administration
    • 10.6.1. Oral
    • 10.6.2. Parenteral
  • 10.7. North America Guillain-Barre Syndrome Market Value Share Analysis, by Distribution Channel
  • 10.8. North America Guillain-Barre Syndrome Market Forecast, by Distribution Channel
    • 10.8.1. Hospital Pharmacies
    • 10.8.2. Retail Pharmacies
    • 10.8.3. Others (Home Care, Clinics, etc.)
  • 10.9. North America Guillain-Barre Syndrome Market Analysis, by Country
  • 10.10. North America Guillain-Barre Syndrome Market Value Share Analysis, by Country
  • 10.11. North America Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Country, 2017-2025
    • 10.11.1. U.S.
    • 10.11.2. Canada
  • 10.12. North America Guillain-Barre Syndrome Market Attractiveness Analysis
    • 10.12.1. By Therapeutics
    • 10.12.2. By Route of Administration
    • 10.12.3. By Distribution Channel
    • 10.12.4. By Country

11. Europe Guillain-Barre Syndrome Market Analysis

  • 11.1. Key Findings
  • 11.2. Europe Guillain-Barre Syndrome Market Overview
  • 11.3. Europe Guillain-Barre Syndrome Market Value Share Analysis, by Therapeutics
  • 11.4. Europe Guillain-Barre Syndrome Market Forecast, by Therapeutics
    • 11.4.1. Intravenous Immunoglobulin
    • 11.4.2. Plasma Exchange
    • 11.4.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
  • 11.5. Europe Guillain-Barre Syndrome Market Value Share Analysis, by Route of Administration
  • 11.6. Europe Guillain-Barre Syndrome Market Forecast, by Route of Administration
    • 11.6.1. Oral
    • 11.6.2. Parenteral
  • 11.7. Europe Guillain-Barre Syndrome Market Value Share Analysis, by Distribution Channel
  • 11.8. Europe Guillain-Barre Syndrome Market Forecast, by Distribution Channel
    • 11.8.1. Hospital Pharmacies
    • 11.8.2. Retail Pharmacies
    • 11.8.3. Others (Home Care, Clinics, etc.)
  • 11.9. Europe Guillain-Barre Syndrome Market Analysis, by Country/Sub-region
  • 11.10. Europe Guillain-Barre Syndrome Market Value Share Analysis, by Country/Sub-region
  • 11.11. Europe Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2025
    • 11.11.1. U.K.
    • 11.11.2. Germany
    • 11.11.3. Italy
    • 11.11.4. France
    • 11.11.5. Spain
    • 11.11.6. Rest of Europe
  • 11.12. Europe Guillain-Barre Syndrome Market Attractiveness Analysis
    • 11.12.1. By Therapeutics
    • 11.12.2. By Route of Administration
    • 11.12.3. By Distribution Channel
    • 11.12.4. By Country/Sub-region

12. Asia Pacific Guillain-Barre Syndrome Market Analysis

  • 12.1. Key Findings
  • 12.2. Asia Pacific Guillain-Barre Syndrome Market Overview
  • 12.3. Asia Pacific Guillain-Barre Syndrome Market Value Share Analysis, by Therapeutics
  • 12.4. Asia Pacific Guillain-Barre Syndrome Market Forecast, by Therapeutics
    • 12.4.1. Intravenous Immunoglobulin
    • 12.4.2. Plasma Exchange
    • 12.4.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
  • 12.5. Asia Pacific Guillain-Barre Syndrome Market Value Share Analysis, by Route of Administration
  • 12.6. Asia Pacific Guillain-Barre Syndrome Market Forecast, by Route of Administration
    • 12.6.1. Oral
    • 12.6.2. Parenteral
  • 12.7. Asia Pacific Guillain-Barre Syndrome Market Value Share Analysis, by Distribution Channel
  • 12.8. Asia Pacific Guillain-Barre Syndrome Market Forecast, by Distribution Channel
    • 12.8.1. Hospital Pharmacies
    • 12.8.2. Retail Pharmacies
    • 12.8.3. Others (Home Care, Clinics, etc.)
  • 12.9. Asia Pacific Guillain-Barre Syndrome Market Analysis, by Country/Sub-region
  • 12.10. Asia Pacific Guillain-Barre Syndrome Market Value Share Analysis, by Country/Sub-region
  • 12.11. Asia Pacific Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2025
    • 12.11.1. China
    • 12.11.2. Japan
    • 12.11.3. India
    • 12.11.4. ASEAN
    • 12.11.5. Rest of Asia Pacific
  • 12.12. Asia Pacific Guillain-Barre Syndrome Market Attractiveness Analysis
    • 12.12.1. By Therapeutics
    • 12.12.2. By Route of Administration
    • 12.12.3. By Distribution Channel
    • 12.12.4. By Country/Sub-region

13. Rest of World Guillain-Barre Syndrome Market Analysis

  • 13.1. Key Findings
  • 13.2. Rest of World Guillain-Barre Syndrome Market Overview
  • 13.3. Rest of World Guillain-Barre Syndrome Market Value Share Analysis, by Therapeutics
  • 13.4. Rest of World Guillain-Barre Syndrome Market Forecast, by Therapeutics
    • 13.4.1. Intravenous Immunoglobulin
    • 13.4.2. Plasma Exchange
    • 13.4.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
  • 13.5. Rest of World Guillain-Barre Syndrome Market Value Share Analysis, by Route of Administration
  • 13.6. Rest of World Guillain-Barre Syndrome Market Forecast, by Route of Administration
    • 13.6.1. Oral
    • 13.6.2. Parenteral
  • 13.7. Rest of World Guillain-Barre Syndrome Market Value Share Analysis, by Distribution Channel
  • 13.8. Rest of World Guillain-Barre Syndrome Market Forecast, by Distribution Channel
    • 13.8.1. Hospital Pharmacies
    • 13.8.2. Retail Pharmacies
    • 13.8.3. Others (Home Care, Clinics, etc.)
  • 13.9. Rest of World Guillain-Barre Syndrome Market Attractiveness Analysis
    • 13.9.1. By Therapeutics
    • 13.9.2. By Route of Administration
    • 13.9.3. By Distribution Channel

14. Company Profiles

  • 14.1. Global Guillain-Barre Syndrome Market Share Analysis, by Company, 2016
  • 14.2. Competition Matrix
  • 14.3. Company Profiles
    • 14.3.1. Grifols S.A.
      • 14.3.1.1. Company Details
      • 14.3.1.2. Business Overview
      • 14.3.1.3. Strategic Overview
      • 14.3.1.4. SWOT Analysis
    • 14.3.2. CSL Behring LLC
      • 14.3.2.1. Company Details
      • 14.3.2.2. Business Overview
      • 14.3.2.3. Strategic Overview
      • 14.3.2.4. SWOT Analysis
    • 14.3.3. Shire plc
      • 14.3.3.1. Company Details
      • 14.3.3.2. Business Overview
      • 14.3.3.3. Strategic Overview
      • 14.3.3.4. SWOT Analysis
    • 14.3.4. Octapharma AG
      • 14.3.4.1. Company Details
      • 14.3.4.2. Business Overview
      • 14.3.4.3. Strategic Overview
      • 14.3.4.4. SWOT Analysis
    • 14.3.5. Nihon Pharmaceutical Co., Ltd.
      • 14.3.5.1. Company Details
      • 14.3.5.2. Business Overview
      • 14.3.5.3. Strategic Overview
      • 14.3.5.4. SWOT Analysis
    • 14.3.6. Akari Therapeutics, PLC
      • 14.3.6.1. Company Details
      • 14.3.6.2. Business Overview
      • 14.3.6.3. Strategic Overview
      • 14.3.6.4. SWOT Analysis
    • 14.3.7. China Biologic Products Holdings, Inc.
      • 14.3.7.1. Company Details
      • 14.3.7.2. Business Overview
      • 14.3.7.3. Strategic Overview
      • 14.3.7.4. SWOT Analysis
    • 14.3.8. Biotest AG
      • 14.3.8.1. Company Details
      • 14.3.8.2. Business Overview
      • 14.3.8.3. Strategic Overview
      • 14.3.8.4. SWOT Analysis
    • 14.3.9. Kedrion s.p.A.
      • 14.3.9.1. Company Details
      • 14.3.9.2. Business Overview
      • 14.3.9.3. Strategic Overview
      • 14.3.9.4. SWOT Analysis

List of Tables

  • TABLE 1 Global Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2015-2025
  • TABLE 2 Global Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2015-2025
  • TABLE 3 Global Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025
  • TABLE 4 Global Guillain-Barre Syndrome Market Value (US$ Mn) Forecast, by Region, 2015-2025
  • TABLE 5 North America Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Country, 2015-2025
  • TABLE 6 North America Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2015-2025
  • TABLE 7 North America Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2015-2025
  • TABLE 8 North America Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025
  • TABLE 9 Europe Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015-2025
  • TABLE 10 Europe Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2015-2025
  • TABLE 11 Europe Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2015-2025
  • TABLE 12 Europe Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025
  • TABLE 13 Asia Pacific Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015-2025
  • TABLE 14 Asia Pacific Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2015-2025
  • TABLE 15 Asia Pacific Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2015-2025
  • TABLE 16 Asia Pacific Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025
  • TABLE 17 Rest of World Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2015-2025
  • TABLE 18 Rest of World Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2015-2025
  • TABLE 19 Rest of World Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025

List of Figures

  • Figure 01: Global Guillain-Barre Syndrome Market Snapshot
  • Figure 02: Global Guillain-Barre Syndrome Market Size (US$ Mn) and Distribution, by Region, 2017 and 2025
  • Figure 03: Global Guillain-Barre Syndrome Market Opportunity Map, 2016
  • Figure 04: Global Guillain-Barre Syndrome Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015-2025
  • Figure 05: Guillain-Barre Syndrome Market Value Share, by Therapeutics (2016)
  • Figure 06: Guillain-Barre Syndrome Market Value Share, by Route of Administration (2016)
  • Figure 07: Guillain-Barre Syndrome Market Value Share, by Distribution Channel (2016)
  • Figure 08: Key Industry Developments
  • Figure 09: Key Market Developments
  • Figure 10: Porter's Five Forces
  • Figure 11: Key Success Factors of Top 3 Players
  • Figure 12: Global Guillain-Barre Syndrome Market Value Share, by Therapeutics, 2017 and 2025
  • Figure 13: Global Guillain-Barre Syndrome Market Revenue (US$ Mn) Forecast, by Intravenous Immunoglobulin, 2015-2025
  • Figure 14: Global Guillain-Barre Syndrome Market Revenue (US$ Mn) Forecast, by Plasma Exchange, 2015-2025
  • Figure 15: Global Guillain-Barre Syndrome Market Revenue (US$ Mn) Forecast, by Others, 2015-2025
  • Figure 16: Global Guillain-Barre Syndrome Market Attractiveness Analysis, by Therapeutics, 2017-2025
  • Figure 17: Global Guillain-Barre Syndrome Market Value Share, by Route of Administration, 2017 and 2025
  • Figure 18: Global Guillain-Barre Syndrome Market Revenue (US$ Mn) Forecast, by Oral, 2015-2025
  • Figure 19: Global Guillain-Barre Syndrome Market Revenue (US$ Mn) Forecast, by Parenteral, 2015-2025
  • Figure 20: Global Guillain-Barre Syndrome Market Attractiveness Analysis, by Route of Administration, 2017-2025
  • Figure 21: Global Guillain-Barre Syndrome Market Value Share, by Distribution Channel, 2017 and 2025
  • Figure 22: Global Guillain-Barre Syndrome Market Revenue (US$ Mn) Forecast, by Hospital Pharmacies, 2015-2025
  • Figure 23: Global Guillain-Barre Syndrome Market Revenue (US$ Mn) Forecast, by Retail Pharmacies, 2015-2025
  • Figure 24: Global Guillain-Barre Syndrome Market Revenue (US$ Mn) Forecast, by Others, 2015-2025
  • Figure 25: Global Guillain-Barre Syndrome Market Attractiveness Analysis, by Distribution Channel, 2017-2025
  • Figure 26: Global Guillain-Barre Syndrome Market Value Share, by Region, 2017 and 2025
  • Figure 27: Global Guillain-Barre Syndrome Market Attractiveness, by Region, 2017-2025
  • Figure 28: North America Guillain-Barre Syndrome Market Value (US$ Mn) and Y-o-Y Growth (%), 2015-2025
  • Figure 29: North America Guillain-Barre Syndrome Market Value Share, by Country, 2017 and 2025
  • Figure 30: North America Guillain-Barre Syndrome Market Value Share, by Therapeutics, 2017 and 2025
  • Figure 31: North America Guillain-Barre Syndrome Market Value Share, by Route of Administration, 2017 and 2025
  • Figure 32: North America Guillain-Barre Syndrome Market Value Share, by Distribution Channel, 2017 and 2025
  • Figure 33: North America Guillain-Barre Syndrome Market Attractiveness Analysis, by Therapeutics, 2017-2025
  • Figure 34: North America Guillain-Barre Syndrome Market Attractiveness Analysis, by Route of Administration, 2017-2025
  • Figure 35: North America Guillain-Barre Syndrome Market Attractiveness Analysis, by Distribution Channel, 2017-2025
  • Figure 36: North America Guillain-Barre Syndrome Market Attractiveness Analysis, by Country, 2017-2025
  • Figure 37: Europe Guillain-Barre Syndrome Market Value (US$ Mn) and Y-o-Y Growth (%), 2015-2025
  • Figure 38: Europe Guillain-Barre Syndrome Market Value Share, by Country/Sub-region, 2017 and 2025
  • Figure 39: Europe Guillain-Barre Syndrome Market Value Share, by Therapeutics, 2017 and 2025
  • Figure 40: Europe Guillain-Barre Syndrome Market Value Share, by Route of Administration, 2017 and 2025
  • Figure 41: Europe Guillain-Barre Syndrome Market Value Share, by Distribution Channel, 2017 and 2025
  • Figure 42: Europe Guillain-Barre Syndrome Market Attractiveness Analysis, by Therapeutics, 2017-2025
  • Figure 43: Europe Guillain-Barre Syndrome Market Attractiveness Analysis, by Route of Administration, 2017-2025
  • Figure 44: Europe Guillain-Barre Syndrome Market Attractiveness Analysis, by Distribution Channel, 2017-2025
  • Figure 45: Europe Guillain-Barre Syndrome Market Attractiveness Analysis, by Country/Sub-region, 2017-2025
  • Figure 46: Asia Pacific Guillain-Barre Syndrome Market Value (US$ Mn) and Y-o-Y Growth (%), 2015-2025
  • Figure 47: Asia Pacific Guillain-Barre Syndrome Market Value Share, by Country/Sub-region, 2017 and 2025
  • Figure 48: Asia Pacific Guillain-Barre Syndrome Market Value Share, by Therapeutics, 2017 and 2025
  • Figure 49: Asia Pacific Guillain-Barre Syndrome Market Value Share, by Route of Administration, 2017 and 2025
  • Figure 50: Asia Pacific Guillain-Barre Syndrome Market Value Share, by Distribution Channel, 2017 and 2025
  • Figure 51: Asia Pacific Guillain-Barre Syndrome Market Attractiveness, by Therapeutics, 2017-2025
  • Figure 52: Asia Pacific Guillain-Barre Syndrome Market Attractiveness, by Route of Administration, 2017-2025
  • Figure 53: Asia Pacific Guillain-Barre Syndrome Market Attractiveness, by Distribution Channel, 2017-2025
  • Figure 54: Asia Pacific Guillain-Barre Syndrome Market Attractiveness, by Country/Sub-region, 2017-2025
  • Figure 55: Rest of World Guillain-Barre Syndrome Market Value (US$ Mn) and Y-o-Y Growth (%), 2015-2025
  • Figure 56: Rest of World Guillain-Barre Syndrome Market Value Share, by Therapeutics, 2017 and 2025
  • Figure 57: Rest of World Guillain-Barre Syndrome Market Value Share, by Route of Administration, 2017 and 2025
  • Figure 58: Rest of World Guillain-Barre Syndrome Market Value Share, by Distribution Channel, 2017 and 2025
  • Figure 59: Rest of World Guillain-Barre Syndrome Market Attractiveness, by Therapeutics, 2017-2025
  • Figure 60: Rest of World Guillain-Barre Syndrome Market Attractiveness, by Route of Administration, 2017-2025
  • Figure 61: Rest of World Guillain-Barre Syndrome Market Attractiveness, by Distribution Channel, 2017-2025
  • Figure 62: Global Guillain-Barre Syndrome Market Share Analysis, by Company (2016)
  • Figure 63: Shire plc Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2017
  • Figure 64: Shire plc Breakdown of Net Sales (%), by Business Segment, 2017
  • Figure 65: Shire plc Breakdown of Net Sales (%), by Geography, 2017
  • Figure 66: CSL Behring LLC Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2017
  • Figure 67: CSL Behring LLC Breakdown of Net Sales (%), by Business Segment, 2017
  • Figure 68: CSL Behring LLC Breakdown of Net Sales (%), by Geography, 2016
  • Figure 69: Grifols, S.A. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2017
  • Figure 70: Grifols, S.A. Breakdown of Net Sales (%), by Business Segment, 2017
  • Figure 71: Grifols, S.A. Breakdown of Net Sales (%), by Region, 2016
  • Figure 72: Octapharma AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2017
  • Figure 73: Octapharma AG: R&D Expenses (US$ Mn), 2014-2017
  • Figure 74: Nihon Pharmaceutical Co., Ltd. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2017
  • Figure 75: Takeda Pharmaceutical Company Limited Revenue (US$ Mn) and Y-o-Y Growth (%), 2013-2016
  • Figure 76: Takeda Pharmaceutical Company Limited Breakdown of Ethical Drugs: Revenue (%), by Region, 2016
  • Figure 77: China Biologic Products Holdings, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013-2016
  • Figure 78: China Biologic Products Holdings, Inc. Breakdown of Net Sales (%), by Business Segment, 2017
  • Figure 79: Biotest AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2013-2016
  • Figure 80: Biotest AG Breakdown of Net Sales (%), by Region, 2016
  • Figure 81: Biotest AG Breakdown of Net Sales (%), by Business Segment, 2016
  • Figure 82: Kedrion S.p.A. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013-2016
  • Figure 83: Kedrion S.p.A. Breakdown of Net Sales (%), by Region, 2016
  • Figure 84: Kedrion S.p.A. Breakdown of Net Sales (%), by Business Segment, 2016